

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-34. (Cancelled)

35. (Currently Amended) A method for identifying a compound that modulates production of IL-4 ~~a Th2-associated cytokine~~ in a cell, comprising

providing an indicator composition comprising (i) a c-maf or v-maf protein ~~maf family protein which binds to a MARE regulatory sequence of a Th2-associated cytokine gene~~ and (ii) a target DNA comprising a ~~MARE~~-regulatory sequence of an IL-4 gene which includes a c-maf responsive element (MARE) ~~a Th2-associated cytokine gene to which said maf family protein binds~~, wherein said indicator composition is an indicator cell or acellular preparation;

contacting the indicator composition with each member of a library of test compounds;

selecting from the library of test compounds a compound of interest that modulates binding of said maf family protein to said target DNA; and determining the effect of the compound of interest on the production of IL-4 ~~a Th2-associated cytokine~~ in a cell to thereby identify a compound that modulates production of IL-4 ~~the Th2 cytokine~~.

36. (Previously Presented) The method of claim 35, wherein the maf family protein is c-Maf.

37-38. (Cancelled)

39. (Currently Amended) The method of claim 35, wherein the effect of the compound of interest on IL-4 ~~Th2-associated cytokine~~ production is determined by

determining the effect of the compound on development of T helper type 1 (Th1) or T helper type (Th2) cells.

40. (Previously Presented) The method of claim 35, wherein the maf family protein is v-maf.

41-42. (Cancelled)

43. (Previously Presented) The method of claim 35, wherein the indicator composition is an indicator cell.

44. (Previously Presented) The method of claim 43, wherein the indicator cell is a lymphoid cell.

45. (Previously Presented) The method of claim 44, wherein the lymphoid cell is a Th2 cell.

46. (Previously Presented) The method of claim 44, wherein the lymphoid cell is a Th1 cell.

47. (Previously Presented) The method of claim 44, wherein the lymphoid cell is a B cell.

48. (Previously Presented) The method of claim 43, wherein the indicator cell is a non-lymphoid mammalian cell.

49. (Previously Presented) The method of claim 43, wherein the indicator cell is a yeast cell.

50-55. (Cancelled)

56. (Previously Presented) The method of claim 44, wherein lymphoid cell is a helper precursor (Thp) cell.

57. (Previously Presented) The method of claim 35, wherein the indicator composition is an acellular preparation.

58-61. (Cancelled)

62. (Currently Amended) The method of claim 35, wherein the maf ~~family~~ protein is recombinantly expressed in a cell.

63. (Currently Amended) The method of claim 35, wherein the cell does not naturally express the maf ~~family~~ protein.

64. (Previously Presented) The method of claim 35, wherein the regulatory sequence comprises about 3 kb of the upstream regulatory sequences of the IL-4 gene.

65. (Currently Amended) The method of claim 35, wherein the regulatory sequence comprises from about nucleotide -157 to about nucleotide ~~residue~~ +58 relative to the start site of transcription of +1 of the IL-4 promoter.

66. (Currently Amended) The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting IL-4 ~~cytokine~~ mRNA.

67. (Currently Amended) The method of claim 35, wherein Th2-associated cytokine production is assessed by detecting the IL-4 ~~cytokine~~ protein.

68. (New) The method of claim 35, wherein the regulatory sequence comprises from about nucleotide -42 to about nucleotide -37 relative to the start site of transcription of +1 of the IL-4 promoter.

69. (New) The method of claim 35, wherein the regulatory sequence comprises from about nucleotide -59 to about nucleotide -27 relative to the start site of transcription of +1 of the IL-4 promoter.